Publicaciones en colaboración con investigadores/as de Hospital Clinico Universitario de Valencia (13)

2023

  1. Impact of the “Zero Resistance” program on acquisition of multidrug-resistant bacteria in patients admitted to Intensive Care Units in Spain. A prospective, intervention, multimodal, multicenter study

    Medicina Intensiva, Vol. 47, Núm. 4, pp. 193-202

2022

  1. Identification of Altered Evoked and Non-Evoked Responses in a Heterologous Mouse Model of Endometriosis-Associated Pain

    Biomedicines, Vol. 10, Núm. 2

2017

  1. Adverse events related to medication in hospitals from the Valencian community. EPIDEA Study 2005-2013

    Revista Espanola de Quimioterapia, Vol. 30, Núm. 5, pp. 319-326

2013

  1. Rilpivirine resistance mutations in HIV patients failing non-nucleoside reverse transcriptase inhibitor-based therapies

    AIDS, Vol. 27, Núm. 1, pp. 81-85

2012

  1. Clinical, virological and biochemical evidence supporting the association of HIV-1 reverse transcriptase polymorphism R284K and thymidine analogue resistance mutations M41L, L210W and T215Y in patients failing tenofovir/emtricitabine therapy

    Retrovirology, Vol. 9

2009

  1. (Enfermedades Infecciosas y Microbiologia Clinica (2009) 27, 4, (222-235))

    Enfermedades Infecciosas y Microbiologia Clinica

2008

  1. Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C

    AIDS, Vol. 22, Núm. 1, pp. 15-21

2007

  1. Baseline serum hepatitis C virus (HCV) RNA level and response at week 4 are the best predictors of relapse after treatment with pegylated interferon plus ribavirin in HIV/HCV-coinfected patients

    Journal of Acquired Immune Deficiency Syndromes, Vol. 45, Núm. 4, pp. 439-444

  2. Outcome of patients with acute promyelocytic leukemia failing to front-line treatment with all-trans retinoic acid and anthracycline-based chemotherapy (PETHEMA protocols LPA96 and LPA99): Benefit of an early intervention

    Leukemia, Vol. 21, Núm. 3, pp. 446-452

  3. Premature treatment discontinuation in HIV/HCV-coinfected patients receiving pegylated interferon plus weight-based ribavirin

    Antiviral Therapy, Vol. 12, Núm. 4, pp. 469-476

  4. Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: The PRESCO trial

    AIDS Research and Human Retroviruses, Vol. 23, Núm. 8, pp. 972-982

  5. Short communication: Hospital-based surveillance for HTLV-1/2 infections in Spain

    AIDS Research and Human Retroviruses, Vol. 23, Núm. 9, pp. 1075-1077

2003

  1. Role of baseline human immunodeficiency virus genotype as a predictor of viral response to tenofovir in heavily pretreated patients

    Journal of Clinical Microbiology, Vol. 41, Núm. 9, pp. 4421-4423